Emerging Therapies in Pulmonary Fibrosis.

Area of Science:

• Pulmonology
• Respiratory Medicine
• Fibrotic Diseases

Background:

• Interstitial lung diseases (ILDs) encompass diverse respiratory disorders marked by inflammation and fibrosis.
• Idiopathic pulmonary fibrosis (IPF), the most prevalent and severe ILD, is a chronic, progressive condition causing irreversible lung function decline.
• Current IPF treatments, including pirfenidone and nintedanib, mitigate lung function decline but do not restore damaged tissue.

Purpose of the Study:

• To review the pathogenesis and prevalence of ILDs.
• To explore current therapeutic strategies for IPF and progressive pulmonary fibrosis.
• To discuss emerging therapies targeting the complex pathophysiology of pulmonary fibrosis.

Main Methods:

• Literature review of ILD pathogenesis, prevalence, and treatment.
• Analysis of current antifibrotic therapies (pirfenidone, nintedanib, nerandomilast).
• Exploration of novel therapeutic approaches for pulmonary fibrosis.

Main Results:

• ILDs are characterized by inflammation and fibrosis, with IPF being a major subtype.
• Existing therapies like pirfenidone and nintedanib offer symptomatic relief and slow disease progression.
• Nerandomilast is a recent FDA-approved treatment for IPF and progressive pulmonary fibrosis.

Conclusions:

• Despite advancements, current treatments for IPF and other ILDs have limitations in reversing lung damage.
• The focus is shifting towards developing novel therapies with enhanced efficacy and safety profiles.
• Future research aims to target the intricate mechanisms of pulmonary fibrosis to arrest or reverse disease progression.